These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 19704053

  • 1. Is it time to widen the use of somatostatin analogs in neuroendocrine tumors?
    Oberg KE.
    J Clin Oncol; 2009 Oct 01; 27(28):4635-6. PubMed ID: 19704053
    [No Abstract] [Full Text] [Related]

  • 2. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
    Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R, PROMID Study Group.
    J Clin Oncol; 2009 Oct 01; 27(28):4656-63. PubMed ID: 19704057
    [Abstract] [Full Text] [Related]

  • 3. Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.
    Oberg K.
    Expert Rev Anticancer Ther; 2009 May 01; 9(5):557-66. PubMed ID: 19445573
    [Abstract] [Full Text] [Related]

  • 4. Neuroendocrine tumors--somatostatin receptor expression and somatostatin analog treatment.
    Janson ET, Oberg K.
    Cancer Chemother Biol Response Modif; 2003 May 01; 21():535-46. PubMed ID: 15338762
    [No Abstract] [Full Text] [Related]

  • 5. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.
    Cives M, Strosberg J.
    Drugs; 2015 May 01; 75(8):847-58. PubMed ID: 25911185
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comments on "Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients".
    Schran HF, Hager DF.
    Pancreas; 2008 Oct 01; 37(3):334-5; author reply 336-7. PubMed ID: 18815560
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge.
    Pusceddu S, Prinzi N, Raimondi A, Corti F, Buzzoni R, Di Bartolomeo M, Seregni E, Maccauro M, Coppa J, Milione M, Mazzaferro V, de Braud F.
    Tumori; 2019 Apr 01; 105(2):113-120. PubMed ID: 29714658
    [Abstract] [Full Text] [Related]

  • 20. Established clinical use of octreotide and lanreotide in oncology.
    Oberg K.
    Chemotherapy; 2001 Apr 01; 47 Suppl 2():40-53. PubMed ID: 11275701
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.